CN103977088A - Compound medicine containing radix paeoniae rubrathe and fluoroquinolones antibacterial drug used for livestock and poultry - Google Patents
Compound medicine containing radix paeoniae rubrathe and fluoroquinolones antibacterial drug used for livestock and poultry Download PDFInfo
- Publication number
- CN103977088A CN103977088A CN201410202807.3A CN201410202807A CN103977088A CN 103977088 A CN103977088 A CN 103977088A CN 201410202807 A CN201410202807 A CN 201410202807A CN 103977088 A CN103977088 A CN 103977088A
- Authority
- CN
- China
- Prior art keywords
- radix paeoniae
- medicine
- poultry
- compound medicine
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a compound medicine containing radix paeoniae rubrathe and fluoroquinolones antibacterial drug used for livestock and poultry. Raw materials of the compound medicine comprise, by weight, 3-30 parts of the fluoroquinolones antibacterial drug and 5-200 parts of the radix paeoniae rubrathe, wherein the fluoroquinolones antibacterial drug is norfloxacin, ciprofloxacin or levofloxacin. According to a research result, drug resistance of bacteria to the antimicrobial medicine can be inverted since the radix paeoniae rubrathe is added to the antimicrobial medicine, so that the treatment effect of the antimicrobial medicine is improved. The compound medicine, which is manufactured into a powder, a tablet, an oral liquid or a particulate agent through a conventional method, is added to livestock and poultry feed for feeding the livestock and poultry with an addition amount being 0.1-7g of a main drug per kilogram of feed. Medicine cost and medicine residue can be reduced greatly, breeding farmers obtain a higher economic benefit and meanwhile foodstuff safety is ensured.
Description
Technical field
The invention belongs to poultry coli-infection treatment technology field, relate in particular to a kind of poultry compound medicine that contains Radix Paeoniae Rubra and fluoroquinolone antibacterial agent.
Background technology
Escherichia coli are common conditioned pathogens, also be normal a kind of disease of sending out, its multiple location severe infections such as chicken acute sepsis, peritonitis, hepatitis, pneumonia, enteritis of can formerly having carried out the coffin upon burial, also can secondary or mixed sending out in virosis, to aquaculture, causes huge economic loss.The beta-lactam lopps antibiotic such as amoxicillin, ampicillin, ceftiofur, ceftriaxone, amoxicillin/clavulanate, ampicillin/sulbactam are the conventional important drugs of this disease of control, along with cultivation scale intensive degree is more and more large, medication is more and more spread unchecked, its Resistant strain is more and more many, also more about the report of Drug Resistance of E. coli.Studies confirm that, one of main mechanism of drug resistance is to produce beta-lactamase, especially extended spectrumβ-lactamase (Extended-Spectrum β-lactamase, ESBLs), this enzyme can be more by force and is hydrolyzed rapidly beta-lactam nucleus, makes this class antibiotic lose antibacterial activity.ESBLs is the main enzyme type of beta-lactamase, and it is not only to cephalo three generations and aztreonam drug resistance, and aminoglycoside, quinolones and sulfonamides are to crossing drug resistant, only to carbapenems, a mould alkene class medicaments insensitive.Many documents have reported colibacillary multi-drug resistant and have produced ESBLs and have substantial connection, both at home and abroad to comparatively pay close attention to.The detection, extraction, enzyme that inventor has carried out food animal source pathogenic bacterium ESBLs recently presses down the researchs such as enzyme protection effect to antibiotic percent hydrolysis and sulbactam, Tazobactam Sodium and Chinese medicine; to part ESBLs, colibacillary drug sensitive test shows, its multidrug resistant rate is apparently higher than non-ESBLs bacterial strain.In addition, result also shows to produce ESBLs bacterial strain not only to the serious drug resistance of the third generation cephalosporins such as ceftiofur, and also to multiple antimicrobial drug drug resistance such as fluoroquinolones, aminoglycoside and sulfonamides, fosfomycin etc., is serious multidrug resistant.Inventor is separated to the escherichia coli that tolerate P-levels mycin produces fosA3 drug resistant gene in producing ESBLs bacterial strain, has more strengthened the drug resistance of antibacterial.Colibacillary drug resistance causes raiser's drug cost to increase, and treatment extends the course for the treatment of, and mortality of livestock increases, and to production, brings larger economic loss, and increases poultry drug residue risk.Therefore, in actual production, need a kind of to no matter whether, the escherichia coli of drug resistance can have the medicine of better therapeutical effect badly, and can shorten treatment course for the treatment of, reduce mortality rate, reducing economic loss and reduce drug residue, is that raiser creates higher economic benefit, also ensures that the mankind's is healthy and safe.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind of poultry compound medicine that contains Radix Paeoniae Rubra and fluoroquinolone antibacterial agent, it can kill antibacterial quickly, overcome antimicrobial drug treatment due to large, the residual height of weak curative effect, consumption and the high defect of cost that drug resistance problem causes, avoided that simple Chinese medicine sterilizing spectrum is narrow, slow problem sterilizes.
For solving above technical problem, the present invention by the following technical solutions: a kind of poultry compound medicine that contains Radix Paeoniae Rubra and fluoroquinolone antibacterial agent, is comprised of the raw material of following weight portion: fluoroquinolone antibacterial agent 3-30 part, Radix Paeoniae Rubra 5-200 part.
Described fluoroquinolone antibacterial agent is norfloxacin, ciprofloxacin or levofloxacin.
Further, described compound medicine is comprised of the raw material of following weight portion: ciprofloxacin 3-20 part and Radix Paeoniae Rubra 40-180 part, or norfloxacin 3-25 part and Radix Paeoniae Rubra 30-190 part.
Described compound medicine is prepared into powder, tablet, oral liquid or granule.
The preparation method of described compound medicine is: Radix Paeoniae Rubra was pulverized to 60 mesh sieves, then mix with pulverous antimicrobial drug, and be prepared into according to a conventional method powder, tablet, oral liquid or granule.
The drug resistance problem existing for current poultry coli-infection, inventor utilizes Lactiflora and antimicrobial drug to form compound medicine.Studies have shown that, in antimicrobial drug, add after Radix Paeoniae Rubra, can reverse the drug resistance of bacteria medicine, thereby improve the therapeutic effect of antimicrobial drug.According to a conventional method this compound medicine is made to powder, tablet, oral liquid or granule, according to the addition of 0.1-7g principal agent/kg feedstuff, add in animal and fowl fodder and feed, can significantly reduce drug cost and drug residue, for raiser creates higher economic benefit, also guaranteed food safety simultaneously.
The specific embodiment
One, the drug resistance inversion effect research of Radix Paeoniae Rubra to antimicrobial drug
Antimicrobial drug itself has the colibacillary effect for the treatment of, but has stronger drug resistance owing to producing the escherichia coli of ESBLs drug resistant gene, causes antimicrobial drug not show good therapeutic effect in normal using dosage situation.
In order to verify the drug resistance inversion effect of Radix Paeoniae Rubra to antimicrobial drug, on 96 orifice plates, adopt microtest tube doubling dilution, first measure antimicrobial drug to producing minimal inhibitory concentration and the subinhibitory concentration of Radix Paeoniae Rubra to product ESBLs and fosA3 drug resistant gene e. coli strains of the e. coli strains of ESBLs and fosA3 drug resistant gene, then in culture medium, added the Radix Paeoniae Rubra of subinhibitory concentration to reuse the minimal inhibitory concentration that microtest tube doubling dilution is cultivated mensuration antimicrobial drug; Utilize continuous passage method in the culture medium that is added with same subinhibitory concentration Radix Paeoniae Rubra and same concentration antimicrobial drug to producing the cultivation of going down to posterity of ESBLs and fosA3 drug resistant gene e. coli strains, until the antimicrobial drug minimal inhibitory concentration observing with go down to posterity before compare and diminish more than 4 times, can be judged as Radix Paeoniae Rubra has drug resistance inversion effect to antibacterial medical instrument.Result of the test statistics is as shown in table 1:
Table 1 subinhibitory concentration (0.5g/mL) Radix Paeoniae Rubra goes down to posterity and causes the variation (μ g/mL) of producing ESBLs and fosA3 escherichia coli Western medicine MIC.
As seen from the above table, antimicrobial drug all reduces more than 4 times the colibacillary minimal inhibitory concentration of drug resistance, can judge that Radix Paeoniae Rubra has drug resistance inversion effect to producing ESBLs and fosA3 drug resistant gene escherichia coli.
Two, the application example of compound medicine of the present invention
According to table 2, fill a prescription and following methods Preparation Example 1-embodiment 8: Radix Paeoniae Rubra was pulverized after 60 mesh sieves, as basic material, again with pulverous antimicrobial drug by weight ratio put into blender and mix, according to a conventional method, compound medicine is prepared into formulation products.
The formula of table 2 embodiment 1-8 and preparation dosage form
| Numbering | Antimicrobial drug | Radix Paeoniae Rubra | Dosage form |
| Embodiment 1 | Ciprofloxacin 3g | 120g | Tablet |
| Embodiment 2 | Ciprofloxacin 10g | 90g | Powder |
| Embodiment 3 | Ciprofloxacin 14g | 40g | Oral liquid |
| Embodiment 4 | Ciprofloxacin 20g | 180g | Granule |
| Embodiment 5 | Norfloxacin 13g | 190g | Tablet |
| Embodiment 6 | Norfloxacin 15g | 85g | Powder |
| Embodiment 7 | Norfloxacin 3g | 5g | Oral liquid |
| Embodiment 8 | Norfloxacin 25g | 30g | Granule |
Inventor obtains compound medicine product by above-described embodiment and has carried out following experiment:
1, the efficacy experiment of the compound medicine product of embodiment 1-4 gained to chicken escherichia coil disease
Clinical symptoms: Guigang, Guangxi chicken house, 25 Day-old Broiler Chickens, there is fragmentary death in chicken group, cuts open the indivedual chickens of inspection and occur the pathological change of bag pericardium liver, typical bacillus coli feature.
Laboratory diagnosis: get pathologic liver and dye sheet, Gram’s staining, micro-Microscopic observation, the gram negative bacilli of red color visible; Tentatively be judged as bacillus coli.By escherichia coli, cultivate, biochemical test is differentiated, judges that chicken infects for bacillus coli, and pcr amplification, proves and produce the ESBLs drug resistant gene that has TEM type.
Test therapeutic regimen: morbidity chicken group is divided into 6 groups of administrations, use embodiment 1 according to the addition administration of 3.5g/kg feedstuff for first group, use embodiment 2 according to the addition administration of 1g/kg feedstuff for second group, use embodiment 3 according to the addition administration of 0.4g/kg feedstuff for the 3rd group, use embodiment 4 according to the addition administration of 1g/kg feedstuff for the 4th group; The 5th group with ciprofloxacin powder according to the addition administration of 0.1g/kg feedstuff, the 6th group with the thick powder of Radix Paeoniae Rubra according to the addition administration of 4g/kg feedstuff; Above six groups of therapeutic regimens all continue to use 5 days.
Effect feedback: after the chicken group medication of first group to the 4th group, sick chicken feed intake rises, and no longer occurs dead chicken, continues to use 3 days, and chicken group be almost recovered; The chicken group medication of the 5th group is after 2 days, and chicken group majority is still unhealthy, still has indivedual chicken deaths, continues to use 3 days, and chicken death phenomenon is not still effectively controlled; The chicken group medication of the 6th group is after 2 days, and chicken group does not have too large remarkable improvement, continues to use 3 days, and chicken death phenomenon is not still effectively controlled.Visible, the compound medicine curative effect that contains Radix Paeoniae Rubra is better than folk prescription.
2, the efficacy experiment of the compound medicine product of embodiment 5-8 gained to the meat-type duck diarrhoea of 20 ages in days
Clinical symptoms: duck field, Nanning, 20 age in days meat-type duck, duck group draws watery stools, has obvious indigested feedstuff in feces.A duck group material feeding is not but long, and the serious duck appearance foot gradually of suffering from diarrhoea is individually soft slowly dead.
Cut open inspection pathological changes: the duck that dies of illness dehydration is more serious, indivedual ducks are still very large, duck liver enlargement, hyperemia, and adularescent film on the liver of part duck, air bag is muddy, and tentative diagnosis is escherichia coli or duck oromeningitis.
Test therapeutic regimen: morbidity duck group divides six groups of administrations, use embodiment 5 according to the addition administration of 3g/kg feedstuff for first group, use embodiment 6 according to the addition administration of 1.3g/kg feedstuff for second group, use embodiment 7 according to the addition administration of 0.5g/kg feedstuff for the 3rd group, use embodiment 8 according to the addition administration of 0.45g/kg feedstuff for the 4th group; The 5th group with norfloxacin powder according to the addition administration of 0.2g/kg feedstuff, the 6th group with the thick powder of Radix Paeoniae Rubra according to the addition administration of 4g/kg feedstuff; Above six groups of therapeutic regimens all continue to use 5 days.
Result of use feedback: first group to the 4th group medication is after 2 days, and sick duck is no longer drawn watery stools, feces is shaped, and no longer occurs dead duck, continues to use 3 days, and duck group be almost recovered; The 5th group of medication is after 2 days, and duck group DeGrain, much still draws watery stools, contain indigested feedstuff, continue to use 3 days some improvement a little, but not good thorough, rare watery stools still occurs, raiser cannot drug withdrawal, have to use the compound medicine of embodiment 6 gained instead, continue to use 2 days, just be almost recovered, re-use 1 day, feces all transfers to normally; The 6th group of medication is after 2 days, and duck does not have too large remarkable improvement, continues to use 3 days, and the duck phenomena of mortality are not still effectively controlled.Visible, the compound medicine that contains Radix Paeoniae Rubra is better than folk prescription to the curative effect of duck diarrhoea.
Claims (4)
1. a poultry compound medicine that contains Radix Paeoniae Rubra and fluoroquinolone antibacterial agent, is characterized in that, consists of: fluoroquinolone antibacterial agent 3-30 part, Radix Paeoniae Rubra 5-200 part the raw material of following weight portion.
2. the poultry compound medicine that contains Radix Paeoniae Rubra and fluoroquinolone antibacterial agent according to claim 1, is characterized in that, described fluoroquinolone antibacterial agent is norfloxacin, ciprofloxacin or levofloxacin.
3. the poultry compound medicine that contains Radix Paeoniae Rubra and fluoroquinolone antibacterial agent according to claim 1, it is characterized in that, described compound medicine is comprised of the raw material of following weight portion: ciprofloxacin 3-20 part and Radix Paeoniae Rubra 40-180 part, or norfloxacin 3-25 part and Radix Paeoniae Rubra 30-190 part.
4. according to the poultry compound medicine that contains Radix Paeoniae Rubra and fluoroquinolone antibacterial agent described in any one in claim 1-3, it is characterized in that, described compound medicine is prepared into powder, tablet, oral liquid or granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410202807.3A CN103977088B (en) | 2014-05-14 | 2014-05-14 | A kind of poultry compound medicine containing Radix Paeoniae Rubra and fluoroquinolone antibacterial agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410202807.3A CN103977088B (en) | 2014-05-14 | 2014-05-14 | A kind of poultry compound medicine containing Radix Paeoniae Rubra and fluoroquinolone antibacterial agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103977088A true CN103977088A (en) | 2014-08-13 |
| CN103977088B CN103977088B (en) | 2017-01-04 |
Family
ID=51269415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410202807.3A Active CN103977088B (en) | 2014-05-14 | 2014-05-14 | A kind of poultry compound medicine containing Radix Paeoniae Rubra and fluoroquinolone antibacterial agent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103977088B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104306645A (en) * | 2014-09-30 | 2015-01-28 | 天津瑞贝特科技发展有限公司 | Injection with antibacterial and anti-inflammatory effects for livestock and poultry and preparation method thereof |
| CN106109549A (en) * | 2016-08-22 | 2016-11-16 | 广西大学 | A kind of poultry compound medicine containing Herba Euphorbiae Humifusae and norfloxacin |
| CN106166173A (en) * | 2016-08-22 | 2016-11-30 | 广西大学 | A kind of poultry compound medicine containing Radix Glycyrrhizae and norfloxacin |
| CN106176942A (en) * | 2016-08-22 | 2016-12-07 | 广西大学 | A kind of poultry compound medicine containing Cortex Cinnamomi and norfloxacin |
| CN106265920A (en) * | 2016-09-21 | 2017-01-04 | 广西大学 | A kind of poultry compound medicine containing Radix Glycyrrhizae, Cortex Cinnamomi and norfloxacin |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101396485A (en) * | 2007-09-29 | 2009-04-01 | 张勇 | Traditional Chinese medicine formula for treating yellow and white scour of suckling pigs |
| CN101554365A (en) * | 2008-04-11 | 2009-10-14 | 天津生机集团股份有限公司 | Norfloxacin transdermal agent for preventing and curing yellow and white scour piglet and preparation method thereof |
| CN101926846A (en) * | 2010-09-01 | 2010-12-29 | 河南新正好生物工程有限公司 | Medicinal composition for treating pullorum disease and preparation method thereof |
| CN101953882A (en) * | 2010-10-15 | 2011-01-26 | 郑州后羿制药有限公司 | Compound microcapsule for treating bacterial disease of livestock and poultry and preparation method thereof |
| CN102247493A (en) * | 2011-07-07 | 2011-11-23 | 河北工程大学 | Chinese medicinal oral liquid capable of eliminating medicine resistance plasmid in chicken bacteria |
| CN103127508A (en) * | 2013-03-18 | 2013-06-05 | 广西大学 | Herba lycopi containing compound composition for treating escherichia coli infected diseases of livestock and poultry |
| CN103301463A (en) * | 2013-06-13 | 2013-09-18 | 广西南宁市桃源兽药厂 | Compound composition containing plumbago zeylanica for treating livestock and poultry escherichia coli infection diseases |
| CN103690952A (en) * | 2013-11-27 | 2014-04-02 | 广西大学 | Compound drug for treating livestock and poultry escherichia coli infected diseases |
-
2014
- 2014-05-14 CN CN201410202807.3A patent/CN103977088B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101396485A (en) * | 2007-09-29 | 2009-04-01 | 张勇 | Traditional Chinese medicine formula for treating yellow and white scour of suckling pigs |
| CN101554365A (en) * | 2008-04-11 | 2009-10-14 | 天津生机集团股份有限公司 | Norfloxacin transdermal agent for preventing and curing yellow and white scour piglet and preparation method thereof |
| CN101926846A (en) * | 2010-09-01 | 2010-12-29 | 河南新正好生物工程有限公司 | Medicinal composition for treating pullorum disease and preparation method thereof |
| CN101953882A (en) * | 2010-10-15 | 2011-01-26 | 郑州后羿制药有限公司 | Compound microcapsule for treating bacterial disease of livestock and poultry and preparation method thereof |
| CN102247493A (en) * | 2011-07-07 | 2011-11-23 | 河北工程大学 | Chinese medicinal oral liquid capable of eliminating medicine resistance plasmid in chicken bacteria |
| CN103127508A (en) * | 2013-03-18 | 2013-06-05 | 广西大学 | Herba lycopi containing compound composition for treating escherichia coli infected diseases of livestock and poultry |
| CN103301463A (en) * | 2013-06-13 | 2013-09-18 | 广西南宁市桃源兽药厂 | Compound composition containing plumbago zeylanica for treating livestock and poultry escherichia coli infection diseases |
| CN103690952A (en) * | 2013-11-27 | 2014-04-02 | 广西大学 | Compound drug for treating livestock and poultry escherichia coli infected diseases |
Non-Patent Citations (1)
| Title |
|---|
| 张芳等: "赤芍提取物体外抑菌活性的研究", 《徐州医学院学报》, vol. 26, no. 05, 31 December 2006 (2006-12-31), pages 418 - 420 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104306645A (en) * | 2014-09-30 | 2015-01-28 | 天津瑞贝特科技发展有限公司 | Injection with antibacterial and anti-inflammatory effects for livestock and poultry and preparation method thereof |
| CN106109549A (en) * | 2016-08-22 | 2016-11-16 | 广西大学 | A kind of poultry compound medicine containing Herba Euphorbiae Humifusae and norfloxacin |
| CN106166173A (en) * | 2016-08-22 | 2016-11-30 | 广西大学 | A kind of poultry compound medicine containing Radix Glycyrrhizae and norfloxacin |
| CN106176942A (en) * | 2016-08-22 | 2016-12-07 | 广西大学 | A kind of poultry compound medicine containing Cortex Cinnamomi and norfloxacin |
| CN106265920A (en) * | 2016-09-21 | 2017-01-04 | 广西大学 | A kind of poultry compound medicine containing Radix Glycyrrhizae, Cortex Cinnamomi and norfloxacin |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103977088B (en) | 2017-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103948930B (en) | A kind of poultry compound medicine containing Radix Paeoniae Rubra and beta-lactam antimicrobial drug | |
| CN103989728A (en) | Acalypha australis L. and beta-lactam antibacterial medicine containing compound medicine for livestock and poultry | |
| CN103690952A (en) | Compound drug for treating livestock and poultry escherichia coli infected diseases | |
| CN103933086A (en) | Creat/amikacin-containing compound medicine for livestock and fowl | |
| CN103127507A (en) | Holly bark containing compound composition for treating escherichia coli infected diseases of livestock and poultry | |
| CN103989730A (en) | Acalypha australis L. and fluoroquinolone antibacterial medicine containing compound medicine for livestock and poultry | |
| CN103977090A (en) | Compound medicine containing radix paeoniae rubrathe and florfenicol and used for livestock and poultry | |
| CN103127508B (en) | Herba lycopi containing compound composition for treating escherichia coli infected diseases of livestock and poultry | |
| CN103977088B (en) | A kind of poultry compound medicine containing Radix Paeoniae Rubra and fluoroquinolone antibacterial agent | |
| CN103989729A (en) | Acalypha australis L. and sulfamonomethoxine sodium containing compound medicine for livestock and poultry | |
| CN103989731A (en) | Acalypha australis L. and florfenicol containing compound medicine for livestock and poultry | |
| CN103948656B (en) | A kind of poultry compound medicine containing Herba Andrographis and fosfomycin | |
| CN104306420A (en) | Balsamiferou blumea herb and sulfamonomethoxine sodium containing compound medicine for livestock and poultry | |
| CN103948691A (en) | Red paeonia/sulfamonomethoxine sodium-containing compound medicine for livestock and fowl | |
| CN103933544B (en) | A kind of poultry compound medicine containing Herba Andrographis and colistin | |
| CN103948677A (en) | Boneset/amoxicillin-containing compound medicine for livestock and fowl | |
| CN103933543B (en) | Utilize the method for Herba Andrographis and colistin treatment poultry coli-infection disease | |
| CN103908670A (en) | Compound composition for treating livestock escherichia coli infection disease | |
| CN104435012A (en) | Pteris multifida and florfenicol-containing compound drug for livestock and poultry | |
| CN104436160A (en) | Balsamiferou blumea herb and colistin containing compound medicine for livestock and poultry | |
| CN104306422A (en) | Balsamiferou Blumea herb and beta-lactam antibacterial drug containing compound medicine for livestock and poultry | |
| CN103948657A (en) | Creat/beta-lactam-antibacterial-agent-containing compound medicine for livestock and fowl | |
| CN103933088A (en) | Method for treating Escherichia coli infection diseases by using creat and antibacterial agents | |
| CN103933087A (en) | Method for treating Escherichia coli infection diseases by using creat and amikacin | |
| CN103933085A (en) | Method for treating Escherichia coli infection diseases by using creat and fosfomycin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |